Staphylococcus aureus FabI: inhibition, substrate recognition, and potential implications for in vivo essentiality.

Structure
Johannes SchiebelCaroline Kisker

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) infections constitute a serious health threat worldwide, and novel antibiotics are therefore urgently needed. The enoyl-ACP reductase (saFabI) is essential for the S. aureus fatty acid biosynthesis and, hence, serves as an attractive drug target. We have obtained a series of snapshots of this enzyme that provide a mechanistic picture of ligand and inhibitor binding, including a dimer-tetramer transition combined with extensive conformational changes. Significantly, our results reveal key differences in ligand binding and recognition compared to orthologous proteins. The remarkable observed protein flexibility rationalizes our finding that saFabI is capable of efficiently reducing branched-chain fatty acid precursors. Importantly, branched-chain fatty acids represent a major fraction of the S. aureus cell membrane and are crucial for its in vivo fitness. Our discovery thus addresses a long-standing controversy regarding the essentiality of the fatty acid biosynthesis pathway in S. aureus rationalizing saFabI as a drug target.

References

Oct 5, 1990·Journal of Molecular Biology·S F AltschulD J Lipman
Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·R T HolmanE Kokmen
Aug 1, 1985·Journal of General Microbiology·A G O'DonnellV Hájek
Dec 15, 1996·Structure·G J Kleywegt, T A Jones
Dec 1, 1996·Antimicrobial Agents and Chemotherapy·F BlancheJ Crouzet
May 13, 1999·Bioinformatics·P GouetF Métoz
Jul 10, 1999·Journal of Molecular Biology·M J StewartC Kisker
Oct 10, 2001·Progress in Lipid Research·R J HeathC O Rock
Sep 18, 2002·Antimicrobial Agents and Chemotherapy·David J PayneWilliam F Huffman
Feb 10, 2004·Applied and Environmental Microbiology·Elizabeth M Fozo, Robert G Quivey
Dec 2, 2004·Acta Crystallographica. Section D, Biological Crystallography·E Krissinel, K Henrick
Feb 5, 2005·American Journal of Physiology. Cell Physiology·Barbara P AtshavesFriedhelm Schroeder
Jun 15, 2005·Annual Review of Biochemistry·Stephen W White Rock
Jul 1, 2005·Protein Science : a Publication of the Protein Society·Xiayang QiuSanjay S Khandekar
Jul 23, 2005·IUBMB Life·T N C RamyaAvadhesha Surolia
Aug 29, 2007·International Journal of Antimicrobial Agents·Hee Soo ParkJin-Hwan Kwak
Jan 16, 2008·Accounts of Chemical Research·Hao Lu, Peter J Tonge
Feb 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dawn M SievertJeffrey C Hageman
Jul 30, 2008·ChemMedChem·Suresh K TipparajuAlan P Kozikowski
May 8, 2009·Journal of Computational Chemistry·Evgeny Krissinel
Jun 30, 2009·Nature Chemical Biology·Bryson D BennettJoshua D Rabinowitz
Aug 29, 2009·Science·Michael A Fischbach, Christopher T Walsh
Nov 3, 2009·The European Respiratory Journal·A Pantosti, M Venditti
Jan 22, 2010·Nature·Wendy BalemansAnil Koul
Mar 30, 2010·Journal of Medicinal Chemistry·Caterina BissantzMartin Stahl
Aug 31, 2010·Biochemical and Biophysical Research Communications·Su Jin KimEunice Eunkyeong Kim
Sep 9, 2010·Infection and Immunity·Yvonne Sun, Mary X D O'Riordan

❮ Previous
Next ❯

Citations

Jul 19, 2014·European Journal of Medicinal Chemistry·Mohamed TakhiHosahalli Subramanya
Feb 11, 2015·Chembiochem : a European Journal of Chemical Biology·Renu Singh, Kevin A Reynolds
Jan 11, 2014·Protein Science : a Publication of the Protein Society·Ling JiangYuhui Dong
May 25, 2015·Biochimica Et Biophysica Acta·Daichi MoritaTeruo Kuroda
Sep 20, 2016·MedChemComm·Jesse A JonesKirk E Hevener
Nov 6, 2015·Journal of Biomolecular Screening·Robel D DemissieLeslie W-M Fung
Jun 29, 2017·The Journal of Physical Chemistry. B·Fang-Yu Lin, Alexander D MacKerell
Jul 22, 2017·Biochimie·Claire MorvanKarine Gloux
Feb 15, 2017·Antimicrobial Agents and Chemotherapy·Karine GlouxAlexandra Gruss
Jun 25, 2014·The Journal of Biological Chemistry·Jiangwei YaoCharles O Rock
May 8, 2019·Chemical Biology & Drug Design·Mohammad A GhattasNoor Atatreh
Apr 7, 2017·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Teruo Kuroda, Wakano Ogawa
Mar 11, 2020·Nature Reviews. Microbiology·Ursula TheuretzbacherGuy E Thwaites
Feb 1, 2020·NPJ Systems Biology and Applications·Mohammad Mazharul IslamRajib Saha
Nov 6, 2020·International Journal of Biological Macromolecules·Rahime Eshaghi MalekshahAli Khaleghian
Jan 23, 2021·Veterinary Sciences·Stephanie A Lynch, Karla J Helbig
Sep 5, 2020·European Journal of Medicinal Chemistry·Preeti RanaSrinivas Nanduri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacillus Cereus Infection

Bacillus Cereus is a gram-positive bacteria that is the cause of some foodborne illnesses and leads to diarrhea and vomiting. Discover the latest research on Bacillus Cereus Infection here.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.

Related Papers

Antimicrobial Agents and Chemotherapy
David J PayneWilliam F Huffman
Acta Crystallographica. Section F, Structural Biology and Crystallization Communications
Shahila MehboobMichael E Johnson
© 2021 Meta ULC. All rights reserved